SCHEMBL15467665

SCHEMBL15467665

N[C@]1(c2ccc(C(F)(F)F)c(Cl)c2)CCOc2cccnc21

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.35
GRM4 Q14833 1/20 0.34
CTNNB1 P35222 1/20 0.33
WNT3A P56704 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
CNR2 P34972 2/20 0.32
SCN9A Q15858 1/20 0.32
TRPV1 Q8NER1 2/20 0.31
P2RX7 Q99572 7/20 0.31
AKT1 P31749 1/20 0.31
AKT2 P31751 1/20 0.31
GRM2 Q14416 1/20 0.30
KMO O15229 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15467667 1.00 TRPM8 (0.35) TRPM8GRM4CTNNB1WNT3ASLC6A2
SCHEMBL15467719 0.87 PDE2A (0.38) TRPM8CTNNB1WNT3AAKT1AKT2
SCHEMBL15467717 0.87 PDE2A (0.38) TRPM8CTNNB1WNT3AAKT1AKT2
Hydrochloric Acid SCHEMBL15568022 0.86 PDE2A (0.37) TRPM8CTNNB1WNT3A
Hydrochloric Acid SCHEMBL16413785 0.86 PDE2A (0.37) TRPM8CTNNB1WNT3A
SCHEMBL15467738 0.86 TRPV3 (0.38) TRPM8SLC6A2SLC6A4SLC6A3
SCHEMBL15467739 0.86 TRPV3 (0.38) TRPM8SLC6A2SLC6A4SLC6A3
SCHEMBL16418760 0.85 TRPM8 (0.35) TRPM8GRM4CTNNB1WNT3ASCN9A
Hydrochloric Acid SCHEMBL15567395 0.84 TRPV3 (0.38) SLC6A2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL15567400 0.84 TRPV3 (0.38) SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885GRM4 408/4885CTNNB1 2569/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885GRM4 408/4885CTNNB1 2569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.